Sell 10/13/2023Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D- from E+ on 10/13/2023 due to an increase in the volatility index and total return index.

Sell 9/28/2023Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to E+ from D- on 9/28/2023 due to a decline in the volatility index.

Sell 8/11/2023Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D- from E+ on 8/11/2023 due to an increase in the volatility index and valuation index.

Sell 8/4/2023Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to E+ from D- on 8/4/2023 due to a decline in the volatility index.

Sell 7/20/2023Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D- from E+ on 7/20/2023 due to an increase in the total return index and volatility index.

Sell 3/23/2023Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to E+ from D- on 3/23/2023 due to a decline in the total return index and volatility index.

Sell 3/14/2023Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 19.01 to 15.84.

Sell 2/23/2023Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.

Sell 2/8/2023Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and volatility index.

Sell 9/12/2022Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D from D- on 9/12/2022 due to a noticeable increase in the total return index and volatility index.

Sell 8/2/2022Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to D- from D on 8/2/2022 due to a decline in the valuation index.

Sell 7/18/2022Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D from D- on 7/18/2022 due to an increase in the volatility index.

Sell 6/1/2022Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to D- from D on 6/1/2022 due to a decline in the total return index and volatility index.

Sell 5/16/2022Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D from E+ on 05/16/2022.

Sell 5/13/2022Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.

Sell 5/11/2022Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D from D- on 5/11/2022 due to an increase in the growth index. Earnings per share increased from -$0.6525 to -$0.6211, and EBIT increased 1.89% from -$32.54M to -$31.93M.

Sell 5/5/2022Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D- from E+ on 05/05/2022.

Sell 4/20/2022Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.

Sell 3/15/2022Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to D- from D on 3/15/2022 due to a significant decline in the total return index, volatility index and efficiency index. Net income declined 37.75% from -$22.75M to -$31.34M, and total capital declined 7.25% from $387.41M to $359.31M.

Sell 11/18/2021Downgrade
Verve Therapeutics, Inc. (VERV) was downgraded to D from D+ on 11/18/2021 due to a substantial decline in the volatility index, efficiency index and total return index. Total capital declined 4.44% from $405.4M to $387.41M.

Sell 9/17/2021Upgraded
Verve Therapeutics, Inc. (VERV) was upgraded to D+ from D on 9/17/2021 due to a significant increase in the total return index.

Sell 9/10/2021None
Verve Therapeutics, Inc. (VERV) was downgraded to D from U on 09/10/2021.